As the proportion of the population affected by CKD increases, there is a particular urgency for LCA research into drugs administered for their kidney protective effects, such as renin-–angiotensin system inhibitors and sodium-glucose cotransporter 2 inhibitors. This evidence concerns the gene SLC5A2 and chronic kidney disease.